CO2021014094A2 - Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos - Google Patents
Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismosInfo
- Publication number
- CO2021014094A2 CO2021014094A2 CONC2021/0014094A CO2021014094A CO2021014094A2 CO 2021014094 A2 CO2021014094 A2 CO 2021014094A2 CO 2021014094 A CO2021014094 A CO 2021014094A CO 2021014094 A2 CO2021014094 A2 CO 2021014094A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- well
- methods
- amatoxin
- hematopoietic stem
- Prior art date
Links
- 231100000729 Amatoxin Toxicity 0.000 title abstract 3
- WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical compound CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 title abstract 2
- 108010014709 amatoxin Proteins 0.000 title abstract 2
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 2
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 208000024908 graft versus host disease Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
Abstract
Se proporcionan amatoxinas, así como conjugados de anticuerpo y fármaco (CAF) que comprenden una amatoxina, así como composiciones y métodos de uso de los mismos. Las composiciones y los métodos proporcionados en el presente documento se pueden utilizar para la terapia del cáncer. También se pueden utilizar para preparar a un paciente para la terapia de trasplante de células madre hematopoyéticas y para mejorar el injerto de trasplantes de células madre hematopoyéticas eliminando de manera selectiva las células madre hematopoyéticas endógenas antes del procedimiento de trasplante. Se proporcionan métodos y composiciones para el tratamiento de diversas enfermedades hematopoyéticas, trastornos metabólicos, cánceres y enfermedades autoinmunitarias, así como para la prevención de la enfermedad del injerto contra el hospedador (EICH).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962838290P | 2019-04-24 | 2019-04-24 | |
PCT/EP2020/061555 WO2020216947A1 (en) | 2019-04-24 | 2020-04-24 | Amatoxin antibody-drug conjugates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021014094A2 true CO2021014094A2 (es) | 2022-01-28 |
Family
ID=70617067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0014094A CO2021014094A2 (es) | 2019-04-24 | 2021-10-22 | Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230135930A1 (es) |
EP (1) | EP3958908A1 (es) |
JP (1) | JP2022530026A (es) |
KR (1) | KR20220003572A (es) |
CN (1) | CN114174317A (es) |
AU (1) | AU2020263959A1 (es) |
BR (1) | BR112021021165A2 (es) |
CA (1) | CA3137373A1 (es) |
CL (2) | CL2021002780A1 (es) |
CO (1) | CO2021014094A2 (es) |
IL (1) | IL287391A (es) |
MX (1) | MX2021012961A (es) |
SG (1) | SG11202110287QA (es) |
WO (1) | WO2020216947A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3268047B9 (en) * | 2015-03-09 | 2024-01-10 | Heidelberg Pharma Research GmbH | Amatoxin-antibody conjugates |
AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
SG11202004192XA (en) * | 2017-11-29 | 2020-06-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd2+ cells |
AU2019310430A1 (en) * | 2018-07-23 | 2021-02-25 | Magenta Therapeutics, Inc. | Use of an anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy |
AR125130A1 (es) * | 2021-03-19 | 2023-06-14 | Heidelberg Pharma Res Gmbh | Conjugados de amatoxina y anticuerpo específicos de linfocitos b |
CA3212655A1 (en) * | 2021-03-31 | 2022-10-06 | Emergence Therapeutics Ag | Anti-nectin-4 antibody exatecan conjugates |
WO2023194539A1 (en) | 2022-04-07 | 2023-10-12 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4363799A (en) | 1979-03-20 | 1982-12-14 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human T cells, and methods for preparing same |
US4515894A (en) | 1979-03-20 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing monoclonal antibody to human T cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
DE3852304T3 (de) | 1987-03-02 | 1999-07-01 | Enzon Lab Inc | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
IT1249051B (it) | 1991-02-26 | 1995-02-11 | Italfarmaco Spa | Immunotossina da anticorpi monoclonali anti-cd5 |
EP0503646A1 (en) | 1991-03-12 | 1992-09-16 | Biogen, Inc. | Monoclonal antibodies recognizing lymphocyte function associated antigen-3 |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US5837491A (en) | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5730979A (en) | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US5817311A (en) | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
DK0687300T3 (da) | 1993-03-05 | 2001-12-31 | Univ Catholique Louvain | LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation |
US5951983A (en) | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
US7592006B1 (en) | 1993-03-05 | 2009-09-22 | Université Catholique de Louvain | Composition comprising the LO-CD2a antibody |
DE4312916C2 (de) | 1993-04-14 | 1995-03-23 | Fresenius Ag | Arzneimittel zur Behandlung von Immunreaktionen |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5795572A (en) | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
EP0749323B1 (en) | 1994-03-08 | 2000-11-29 | Dana-Farber Cancer Institute | Methods for modulating t cell anergy |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU5981796A (en) | 1995-06-07 | 1997-01-09 | Thera Pro | Pyrularia thionin containing immunotoxins and immunotoxin-li ke conjugates |
PT871490E (pt) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
US6218519B1 (en) | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
US6764688B2 (en) | 1996-09-03 | 2004-07-20 | Kaneka Corporation | Method for inducing immunosuppressive cells and a culture device to be used therefor |
CA2264227A1 (en) | 1996-09-27 | 1998-04-02 | Raymond A. Firestone | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
US6849258B1 (en) | 1997-07-18 | 2005-02-01 | Universite Catholique De Louvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US6358506B1 (en) | 1997-11-05 | 2002-03-19 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
CA2309919A1 (en) | 1997-11-14 | 1999-05-27 | The General Hospital Corporation | Treatment of hematologic disorders |
EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
AU2980900A (en) | 1999-02-04 | 2000-08-25 | General Hospital Corporation, The | Methods for human allografting |
US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
US6541611B1 (en) | 1999-06-18 | 2003-04-01 | Universite Catholique De Louvain | LO-CD2b antibody |
US20040052793A1 (en) | 2001-02-22 | 2004-03-18 | Carter Paul J. | Caspase activivated prodrugs therapy |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US20050069538A1 (en) | 2003-09-18 | 2005-03-31 | Gregorio Aversa | Therapeutic binding molecules |
AU2002250236A1 (en) | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
EP1461081A4 (en) | 2001-12-03 | 2006-05-17 | Abgenix Inc | ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION |
US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
PL375144A1 (en) | 2002-07-30 | 2005-11-28 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
CA2497628A1 (en) | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
KR100694508B1 (ko) | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Hbbk4항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
KR100745488B1 (ko) | 2006-07-04 | 2007-08-02 | 학교법인 울산공업학원 | 항-4-1bb 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물 |
ITBO20070242A1 (it) | 2007-04-03 | 2008-10-04 | Gsg Int Spa | Profilato per serramenti scorrevoli, metodo per la realizzazione del profilato, e serramento ottenuto con il profilato stesso. |
KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
US20110229460A1 (en) | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
US20110250203A1 (en) | 2008-08-29 | 2011-10-13 | Symphogen A/S | Anti-cd5 antibodies |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
LT3192529T (lt) | 2009-04-08 | 2020-06-25 | Faulstich, Heinz, Dr. | Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai |
US20120076722A1 (en) | 2009-05-14 | 2012-03-29 | University Of Maryland, Baltimore | Methods for treating cancers and diseases associated with 4-1bb (cd137) expression |
EP2430051B1 (en) | 2009-05-14 | 2016-03-23 | Institut National de la Santé et de la Recherche Medicale | Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases |
WO2011031063A2 (ko) | 2009-09-09 | 2011-03-17 | 울산대학교 산학협력단 | 항 4-1bb 항체를 포함하는 대사성 질환의 예방 또는 치료용 조성물 |
SG10201501784YA (en) | 2009-12-07 | 2015-05-28 | Univ Leland Stanford Junior | Methods for enhancing anti-tumor antibody therapy |
KR20110085038A (ko) | 2010-01-19 | 2011-07-27 | 울산대학교 산학협력단 | 항 cd137-항체 및 독소 결합물을 이용한 cd137 양성세포의 제거방법 |
SG188471A1 (en) | 2010-09-08 | 2013-04-30 | Yeda Res & Dev | An immunosuppressive drug combination for a stable and long term engraftment |
RU2710717C2 (ru) | 2010-09-09 | 2020-01-10 | Пфайзер Инк. | Молекулы, связывающиеся с 4-1ВВ |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
DK2699598T3 (en) | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
JP2015504047A (ja) | 2011-12-22 | 2015-02-05 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 安定かつ長期の生着のための併用療法 |
US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
US20150218220A1 (en) | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
EP2968590B1 (en) * | 2013-03-15 | 2018-09-05 | Novartis AG | Antibody drug conjugates |
IL290330B2 (en) | 2013-12-19 | 2023-09-01 | Seagen Inc | Methylene carbamate binders for use with drug-targeting conjugates |
ES2783026T3 (es) | 2014-02-04 | 2020-09-16 | Pfizer | Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer |
JP2017517506A (ja) | 2014-05-21 | 2017-06-29 | ファイザー・インコーポレイテッド | 癌を処置するための抗ccr4抗体および4−1bbアゴニストの併用 |
WO2015188047A1 (en) | 2014-06-06 | 2015-12-10 | University Of Maryland, Baltimore | ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY |
ES2726645T3 (es) | 2014-08-01 | 2019-10-08 | Inst Nat Sante Rech Med | Un anticuerpo anti-CD45RC para usar como medicamento |
US20170247455A1 (en) | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
ES2740907T3 (es) | 2014-10-03 | 2020-02-07 | Synaffix Bv | Enlazador de sulfamida, conjugados de los mismos y métodos de preparación |
US9938323B2 (en) | 2014-11-06 | 2018-04-10 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
EP3026060A1 (en) | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
CA3224830A1 (en) | 2015-01-08 | 2016-07-14 | Biontech Ag | Agonistic tnf receptor binding agents |
CN107921104A (zh) | 2015-02-22 | 2018-04-17 | 索伦托治疗有限公司 | 结合cd137的抗体疗法 |
EP3268047B9 (en) * | 2015-03-09 | 2024-01-10 | Heidelberg Pharma Research GmbH | Amatoxin-antibody conjugates |
EP3286225B1 (en) | 2015-04-23 | 2020-07-01 | Baylor College of Medicine | Cd5 chimeric antigen receptor for adoptive t cell therapy |
MX2017014699A (es) | 2015-05-21 | 2018-04-11 | Alligator Bioscience Ab | Polipeptidos novedosos. |
JP6845846B6 (ja) | 2015-09-22 | 2021-04-21 | ディンフー バイオターゲット カンパニー リミテッド | 抗ヒトcd137の完全ヒト抗体及びその用途 |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
US20170129128A1 (en) | 2015-11-05 | 2017-05-11 | Black & Decker Inc. | Saw |
EP3394770A4 (en) | 2015-12-22 | 2019-05-01 | 3M Innovative Properties Company | HEALTH MANAGEMENT SYSTEM WITH MULTIDIMENSIONAL PERFORMANCE REPRESENTATION |
EP3408294A1 (en) | 2016-01-25 | 2018-12-05 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
EP3426305A4 (en) | 2016-03-07 | 2020-01-08 | Actinium Pharmaceuticals, Inc. | STABILIZED RADIOACTIVELY MARKED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS |
US11104739B2 (en) | 2016-04-14 | 2021-08-31 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody |
CN115181164A (zh) | 2016-04-20 | 2022-10-14 | 杭州多禧生物科技有限公司 | 鹅膏毒素的衍生物及其与细胞结合分子的偶联 |
US11013816B2 (en) * | 2016-05-31 | 2021-05-25 | Sorrento Therapeutics, Inc. | Antibody drug conjugates having derivatives of amatoxin as the drug |
US20190338040A1 (en) | 2016-07-20 | 2019-11-07 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
JP7274417B2 (ja) | 2016-11-23 | 2023-05-16 | イミュノア・セラピューティクス・インコーポレイテッド | 4-1bb結合タンパク質及びその使用 |
WO2018115466A1 (en) | 2016-12-23 | 2018-06-28 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
WO2019027754A1 (en) | 2017-08-01 | 2019-02-07 | Eli Lilly And Company | ANTI-CD137 ANTIBODIES |
MX2019004692A (es) | 2017-01-06 | 2019-11-08 | Eutilex Co Ltd | Anticuerpos 4-1bb anti-humano y usos de los mismos. |
SG10202102897PA (en) | 2017-01-20 | 2021-04-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
KR20200035966A (ko) | 2017-07-11 | 2020-04-06 | 콤파스 테라퓨틱스 엘엘씨 | 인간 cd137에 결합하는 작동자 항체 및 이의 용도 |
GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
AU2018314668B2 (en) * | 2017-08-07 | 2022-06-02 | Heidelberg Pharma Research Gmbh | Novel method for synthesizing amanitins |
CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
WO2019197654A1 (en) | 2018-04-13 | 2019-10-17 | Heidelberg Pharma Research Gmbh | Targeted amatoxin conjugate for the treatment of solid tumors |
SG11202100607RA (en) | 2018-07-31 | 2021-02-25 | Heidelberg Pharma Res Gmbh | Humanized antibodies against psma |
-
2020
- 2020-04-24 MX MX2021012961A patent/MX2021012961A/es unknown
- 2020-04-24 EP EP20724752.9A patent/EP3958908A1/en active Pending
- 2020-04-24 AU AU2020263959A patent/AU2020263959A1/en active Pending
- 2020-04-24 WO PCT/EP2020/061555 patent/WO2020216947A1/en unknown
- 2020-04-24 CA CA3137373A patent/CA3137373A1/en active Pending
- 2020-04-24 US US17/605,766 patent/US20230135930A1/en active Pending
- 2020-04-24 SG SG11202110287QA patent/SG11202110287QA/en unknown
- 2020-04-24 US US16/858,509 patent/US20200407440A1/en not_active Abandoned
- 2020-04-24 BR BR112021021165A patent/BR112021021165A2/pt unknown
- 2020-04-24 KR KR1020217038138A patent/KR20220003572A/ko active Search and Examination
- 2020-04-24 CN CN202080046209.5A patent/CN114174317A/zh active Pending
- 2020-04-24 JP JP2021562940A patent/JP2022530026A/ja active Pending
-
2021
- 2021-10-19 IL IL287391A patent/IL287391A/en unknown
- 2021-10-22 CO CONC2021/0014094A patent/CO2021014094A2/es unknown
- 2021-10-22 CL CL2021002780A patent/CL2021002780A1/es unknown
-
2022
- 2022-11-10 CL CL2022003143A patent/CL2022003143A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20200407440A1 (en) | 2020-12-31 |
CN114174317A (zh) | 2022-03-11 |
AU2020263959A1 (en) | 2021-11-25 |
KR20220003572A (ko) | 2022-01-10 |
WO2020216947A1 (en) | 2020-10-29 |
US20230135930A1 (en) | 2023-05-04 |
MX2021012961A (es) | 2021-11-25 |
CA3137373A1 (en) | 2020-10-29 |
CL2022003143A1 (es) | 2023-04-21 |
SG11202110287QA (en) | 2021-10-28 |
JP2022530026A (ja) | 2022-06-27 |
EP3958908A1 (en) | 2022-03-02 |
BR112021021165A2 (pt) | 2022-01-04 |
CL2021002780A1 (es) | 2022-06-10 |
IL287391A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002780A1 (es) | Conjugados de anticuerpo y fármaco de amatoxina y usos de los mismos | |
CO2020004906A2 (es) | Composiciones y métodos para la eliminación de células cd117+ | |
HN2011001195A (es) | Compuestos que expanden las celulas madre hematopoieticas | |
CO2021006259A2 (es) | Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos | |
GT200600297A (es) | Nuevos anticuerpos anti-madcam | |
WO2019084057A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
AR105808A1 (es) | Compuestos de amida para el tratamiento de trastornos médicos | |
CO6382119A2 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
CR20120313A (es) | Antagonistas de espiro-oxindol de mdm2 | |
ES2572211T3 (es) | Regeneración de músculo esquelético utilizando células madre mesenquimales | |
CO2020006855A2 (es) | Composiciones y métodos para el agotamiento de células cd2+ | |
MX2021002932A (es) | Metodo para obtener una poblacion enriquecida de celulas madre mesenquimales funcionales, celulas obtenidas de la misma y composiciones que las comprenden. | |
MX2021004579A (es) | Métodos para trasplante de células madre hematopoyéticas alogénicas. | |
CL2020003319A1 (es) | Receptores del factor de crecimiento quiméricos | |
CO2020007275A2 (es) | Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas | |
EA202090947A1 (ru) | Композиции и способы для истощения cd5+ клеток | |
AR047005A1 (es) | Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico | |
AR120057A1 (es) | Composiciones neoantigénicas y usos de estas | |
ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
CL2021002735A1 (es) | Anticuerpos anti-pd-l1 modificados y métodos y usos para el tratamiento de una enfermedad neurodegenerativa | |
WO2020219778A3 (en) | Anti-cd117 antibody-drug conjugates and uses thereof | |
ECSP078006A (es) | Fracción activa de un extracto de látex de las plantas de la familia de las euphorbiaceae en solvente polar | |
BR112022011284A2 (pt) | Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica |